With a research interest in the area of bone biology, Amgen’s Dr. David Lacey leads the team that, 12 yeas ago, discovered a fully human monoclonal antibody with a positive effect on bone density. Today, the RANK ligand inhi
Dr. Eliseo Salinas, Chief Scientific Officer and Executive Vice President of Research and Development, talks to NGP’s Rebecca Goozee about Shire’s successful formula and the outlook for the future.
Dietram Scheufele and Elizabeth Corley explain the parallels between politics and nanotechnology.
Cellular assays have become common in high throughput screening (HTS), as companies try to utilize assays that will result in more biologically relevant data.
Pharmaceutical companies are laboring under an overall decline in R&D productivity. It is a headache that has plagued the industry for the past three decades and shows no signs of letting up. And with the growing pressure from the public need for (an